Head and Neck Squamous Cell Carcinoma
495
129
197
126
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
61 trials with published results (12%)
Research Maturity
126 completed trials (25% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.9%
49 terminated out of 495 trials
72.0%
-14.6% vs benchmark
5%
25 trials in Phase 3/4
48%
61 of 126 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 126 completed trials
Clinical Trials (495)
A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
Study of CHS-114 in Participants With Advanced Solid Tumors
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Heavy Strength Training in Head and Neck Cancer Survivors
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A Study of IOV-5001 in Adults With Advanced Solid Tumors
MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists